A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA)
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Faricimab (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms TENAYA
- Sponsors Roche
- 01 Nov 2019 Planned End Date changed from 30 Nov 2022 to 21 Aug 2022.
- 15 Feb 2019 Status changed from not yet recruiting to recruiting.
- 05 Nov 2018 New trial record